



# The Illinois Medical Bulletin



## The Relationship Between Obesity and the Pathogenesis of Non-alcoholic Fatty Liver Disease: A Review of the Literature from 2000-2010

<sup>1</sup>A.Beaver, <sup>2</sup>A. Bennett

<sup>1,2</sup> University of Illinois College of Medicine

Corresponding Email : [drbeaver126363@gmail.com](mailto:drbeaver126363@gmail.com)

### Article History :

Received date : 2010/10/12  
Revised date : 2010/11/28  
Accepted date : 2010/12/09  
Published date : 2011/01/13



**Copyright:** © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

---

### ABSTRACT

---

**Introduction:** The first decade of the 21st century saw a dramatic rise in the global prevalence of obesity. Coinciding with this epidemic was the recognition of Non-alcoholic Fatty Liver Disease (NAFLD) as a leading cause of chronic liver injury worldwide. This review aims to synthesise the key scientific literature published between 2000 and 2010 that elucidated the critical relationship between obesity and the pathogenesis of NAFLD.

**Literature Review:** Research during this period firmly established obesity, and its associated insulin resistance, as the principal driver of NAFLD. The "two-hit" hypothesis emerged as the dominant explanatory model. The "first hit" was defined as hepatic steatosis, resulting from increased fatty acid flux to the liver driven by insulin resistance. The "second hit," which promotes progression to the more severe Non-alcoholic Steatohepatitis (NASH), was attributed to factors like oxidative stress, mitochondrial dysfunction, and pro-inflammatory cytokines. Crucially, studies in this era redefined adipose tissue as an active endocrine organ. The roles of

adipokines, such as the pro-inflammatory effects of leptin resistance and the loss of the protective, insulin-sensitising effects of adiponectin, were identified as key links between excess adiposity and liver inflammation and fibrosis.

**Conclusion:** The body of evidence from 2000-2010 solidified the conceptual framework viewing NAFLD as the hepatic manifestation of the metabolic syndrome. It confirmed that obesity, through the mechanism of insulin resistance and a dysregulated adipokine profile, is the primary catalyst for both the development of hepatic steatosis and its inflammatory progression to NASH.

**Keywords:** Obesity, Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH), Insulin Resistance, Metabolic Syndrome.

---

## **INTRODUCTION**

---

The period between 2000 and 2010 was marked by an intensifying global public health crisis: the obesity epidemic. As the prevalence of excess body weight increased, so too did the recognition of its numerous co-morbidities. Within the field of hepatology, this decade was transformative, as Non-alcoholic Fatty Liver Disease (NAFLD) evolved from a little-known condition to being identified as the most common cause of chronic liver disease in Western countries (Angulo, 2002). NAFLD encompasses a spectrum of conditions, ranging from simple hepatic steatosis (fatty liver) to Non-alcoholic Steatohepatitis (NASH), an aggressive form characterised by inflammation and hepatocyte injury, which can progress to cirrhosis and hepatocellular carcinoma.

The parallel rise of obesity and NAFLD prompted intense investigation into their connection. It became evident that NAFLD was not an isolated liver problem but was intrinsically linked to systemic metabolic dysfunction. This literature review will synthesise the key scientific publications from the pivotal decade of 2000-2010 that established the association between obesity and the pathogenesis of NAFLD, focusing on the role of insulin resistance, the prevailing pathogenic models, and the emerging understanding of adipose tissue biology.

---

## **LITERATURE REVIEW**

---

The link between obesity and NAFLD was unequivocally cemented in the literature of the early 21st century. Epidemiological studies consistently demonstrated a high prevalence of NAFLD

in individuals with obesity, with some reports suggesting that up to 90% of patients undergoing bariatric surgery had evidence of fatty liver disease. This strong clinical association demanded a mechanistic explanation.

The most widely accepted pathogenic paradigm during this period was the "two-hit" hypothesis, comprehensively reviewed and popularised by authors such as Farrell and Larter (2006). The "first hit" was proposed to be the development of hepatic steatosis. This was understood to be a direct consequence of insulin resistance, a hallmark of visceral obesity. Insulin resistance in adipose tissue leads to uncontrolled lipolysis, releasing a flood of non-esterified fatty acids into the circulation. A significant portion of these fatty acids are taken up by the liver, overwhelming its capacity for beta-oxidation and export as very-low-density lipoproteins (VLDL), thus leading to triglyceride accumulation within hepatocytes (Marchesini et al., 2001).

While simple steatosis was considered relatively benign, the progression to NASH required a "second hit." Research in this decade focused on identifying these secondary insults that promote necroinflammation and fibrosis in the fat-laden liver. Key factors identified included increased oxidative stress from mitochondrial dysfunction and lipid peroxidation, and the activity of pro-inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF- $\alpha$ ), which was known to be overexpressed in the adipose tissue of obese individuals (Sanyal et al., 2001). These factors were shown to cause hepatocyte injury, trigger an inflammatory cascade, and activate hepatic stellate cells, initiating the fibrotic process.

A critical conceptual advance during this era was the re-characterisation of white adipose tissue from a passive energy storage site to a highly active endocrine organ. This shift was fundamental to understanding the obesity-NASH connection. Studies highlighted the role of adipokines—hormones secreted by fat cells. In obese states, there is a characteristic dysregulation in adipokine secretion. Levels of adiponectin, an insulin-sensitising and anti-inflammatory hormone, were found to be paradoxically low, depriving the liver of a key protective factor (Tilg and Moschen, 2006). Conversely, levels of leptin, another adipokine, are elevated in obesity. While leptin normally regulates satiety, the state of leptin resistance that develops in obesity, coupled with high leptin levels, was shown to have direct pro-fibrogenic effects on the liver, further driving disease progression (Diehl, 2002). This endocrine

dysfunction provided a direct molecular link between the obese state and specific pathogenic events within the liver.

---

### **CONCLUSION**

---

The decade between 2000 and 2010 was a watershed period for understanding the relationship between obesity and Non-alcoholic Fatty Liver Disease. The literature published during this time moved beyond simple association to establish a robust, mechanistic framework. Obesity, through the induction of systemic insulin resistance, was confirmed as the fundamental "first hit" leading to hepatic steatosis.

The "two-hit" model provided a compelling narrative for the progression to the more aggressive phenotype of NASH, implicating oxidative stress and inflammation as key secondary events. Perhaps most importantly, the recognition of adipose tissue as an endocrine organ that secretes a host of metabolically active adipokines provided the crucial missing link, explaining how excess and dysfunctional fat tissue could directly promote inflammation and fibrosis in the liver. The research from this era firmly established NAFLD as the hepatic manifestation of the metabolic syndrome, a concept that continues to guide clinical practice and research today.

---

### **REFERENCES**

---

- Angulo, P. (2002) 'Nonalcoholic fatty liver disease', *New England Journal of Medicine*, 346(16), pp. 1221-1231.
- Diehl, A.M. (2002) 'Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease as a component of the metabolic syndrome', *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 282(1), pp. G1-G5.
- Farrell, G.C. and Larter, C.Z. (2006) 'Nonalcoholic fatty liver disease: from steatosis to cirrhosis', *Hepatology*, 43(S1), pp. S99-S112.
- Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M. and Melchionda, N. (2001) 'Nonalcoholic fatty liver disease: a feature of the metabolic syndrome', *Diabetes*, 50(8), pp. 1844-1850.
- Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J., Sterling, R.K., Luketic, V.A., Shiffman, M.L. and Clore, J.N. (2001) 'Nonalcoholic steatohepatitis: association

of insulin resistance and mitochondrial abnormalities', *Gastroenterology*, 120(5), pp. 1183-1192.

Tilg, H. and Moschen, A.R. (2006) 'Adipocytokines: mediators linking adipose tissue, inflammation and immunity', *Nature Reviews Immunology*, 6(10), pp. 772-783.